Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Regen BioPharma Inc RGBP

Regen BioPharma Inc. is a biotechnology company. The Company is engaged on the immunology and immunotherapy space. The Company is focused on novel technologies through pre-clinical and Phase I/ II clinical trials. It is involved on mRNA and small molecule therapies for treating cancer and autoimmune disorders. It is also developing products treating blood disorders using small molecules and gene silencing (DiffronC), treating cancer with cellular immunotherapy (dCellVax, tCellVax, Dura-CAR, KimerApt), modulating key molecular processes in cancer stem cell through its patented molecular targeting approaches (BORIS), and repairing damaged bone marrow in patients with aplastic anemia and chemotherapy/radiotherapy treated cancer patients (HemaXellerate). HemaXellerate is a personalized cellular therapeutic product designed to stimulate blood production in patients. tCellVax is a cell-based immunotherapy that stimulates the patient’s immune system through gene silencing of NR2F6.


OTCPK:RGBP - Post by User

Post by averagepennieson Dec 05, 2023 11:27am
69 Views
Post# 35769119

Regen BioPharma, Inc. to Present at the Emerging Growth Conf

Regen BioPharma, Inc. to Present at the Emerging Growth Conf

Regen BioPharma, Inc. invites individual and institutional investors as well as advisors and analysts, to attend its real-time, interactive presentation at the Emerging Growth Conference.

SAN DIEGO, Calif. Dec. 5, 2023 /PRNewswire/ -- Regen BioPharma, Inc. (OTC PINK: RGBP) (OTC PINK: RGBPP), a biotechnology company advancing a diverse pre-clinical pipeline spanning cell therapies, RNA vaccines, RNA and DNA therapeutics and small molecule drugs will be presenting at the Emerging Growth Conference on December 7, 2023 (https://emerginggrowth.com/conference/).

This live, interactive online event will give existing shareholders and the investment community the opportunity to interact with the Company's CEO, Dr. David Koos, in real time.  Please ask your questions during the event and Dr. Koos and his team will do their best to get through as many of them as possible.

"We plan to use this time to discuss our progress and timeline regarding our DuraCAR program as well as update our shareholders on our financial plan," says Dr. David Koos, CEO and Chairman of the Company. 

Regen BioPharma, Inc. will be presenting at 3:25 - 3:35 Eastern time on Thursday, December 7, 2023.  Please register here to ensure you are able to attend the conference and receive any updates that are released https://goto.webcasts.com/starthere.jsp?ei=1641026&tp_key=4a8f04de2b&sti=rgbp.

If attendees are not able to join the event live on the day of the conference, an archived webcast will also be made available on EmergingGrowth.com.

https://www.prnewswire.com/news-releases/regen-biopharma-inc-to-present-at-the-emerging-growth-conference-on-december-7-2023-302005649.html

<< Previous
Bullboard Posts
Next >>